NCCN Guidelines® Insights - Cancer-Associated Venous Thromboembolic Disease, Version 1.2015
The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.
Target Audience
This activity has been designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Cancer- Associated Venous Thromboembolic Disease
Available Credit
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician
Price
Required Hardware/software
To access this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for article and certificate viewing/printing